↑ Grab this Headline Animator

Decreased Growth Rate for the Antihypertensive Market as Companies...

Research and Markets (http://www.researchandmarkets.com/reports/c43152) has announced the addition of Commercial Insight: Antihypertensives - New Challenges for a Maturing Market to their offering.



The author expects the antihypertensive market to exceed $40bn by 2015 across the seven major markets, with novel treatments and the market-leading ARBs delivering much of this value. However, significant hurdles exist, and pharmaceutical companies need to carefully design marketing campaigns and pricing structures for their products.



Scope of this title:

- Event-driven sales forecasts, for the period 2006-2015, for the US, Japan, France, Germany, Italy, Spain and the UK, plus a global overview

- Discussion of individual products in four main classes; beta blockers (BBs), CCBs, ACE inhibitors and the ARBs

- Profiles of the country and market specific issues which will impact future sales in the market including generic erosion and new product launches

- Commercial impact case studies on R&D innovation, clinical trial data and European healthcare reform



Highlights of this title:

- The growth rate of the antihypertensive market is declining. These changes reflect the challenges faced by pharmaceutical companies over the next decade, as brand erosion and healthcare reforms impact heavily. The slow and declining growth rate does not reflect a stationary market, but the battle between the drugs that make up the market

- Cozaars patent expiry in the US has the potential to alter the structure of the antihypertensive market dramatically. Threats of generic substitution and money-saving healthcare strategies which have plagued other markets are now approaching the successful ARB class, and will have an impact on the whole antihypertensive market.

- Large pharmaceutical companies that have established themselves in the cardiovascular arena are steering away from development in the antihypertensives market. While still continuing to enjoy large revenues from its cardiovascular arm, the research and development of Novartis shows that it is now investing elsewhere.



Reasons to order your copy:

- Quantify the future size and scope of the hypertension market and the potential for new products

- Analyze options to expand commercial potential through pursuit of new indications

- Formulate successful launch strategies to succeed in a highly competitive market



Products Mentioned:

- Rasilez

- Exforge

- C7 BBs

- C8 CCBs

- C9 ACEs

- C9 ARBs



For more information visit http://www.researchandmarkets.com/reports/c43152



Source: Datamonitor



Laura Wood

Senior Manager

Research and Markets

Fax: +353 1 684 99 77

↑ Grab this Headline Animator

---

This article has been robotically scanned and tagged by Prnewsnow with the following search tags. No human manipulation of these tags take place.
| Modern | Mid Century | bradley friedman director |

---

4911 readers online...

, Local News